"The results from this trial, the first to assess a biologic medicine in children under 12 with atopic dermatitis
, are very important because of the significant unmet needs in this patient population.
Release date- 06082019 - A pivotal Phase 3 trial evaluating Dupixent (dupilumab) to treat severe atopic dermatitis
in children aged 6 to 11 years met its primary and secondary endpoints.
In addition, Dupixent comes in 200 mg and 300 mg doses in pre-filled syringe for adolescents with atopic dermatitis
. It is intended for injection under the skin and is given every other week following an initial dose (400 mg and 600 mg, respectively).
Identification of atopic dermatitis
subgroups in children from 2 longitudinal birth cohorts.
Maruho Announces Positive Phase 3 Results of Nemolizumab in Patients with Atopic Dermatitis
For the treatment of atopic dermatitis
, omalizumab has mostly been used in doses ranging from 300 to 450 mg every 2 to 4 weeks (5-7).
Presentations on Dupixent (dupilumab) include results from a pooled analysis of the Phase 3 clinical trials (SOLO 1 and SOLO 2) in adult patients with moderate-to-severe atopic dermatitis
and a Phase 3 trial that evaluated the efficacy and safety of Dupixent in adolescents with moderate-to-severe atopic dermatitis
inadequately controlled with topical prescription therapies.
The researchers found that the prevalence of atopic dermatitis
was 7.3 percent (95 percent confidence interval [CI], 5.9 to 8.8), with 60.1 (95 percent CI, 56.1 to 64.1 percent), 28.9 (95 percent CI, 25.3 to 32.7 percent), and 11 percent (95 percent CI, 8.6 to 13.7 percent) classified as mild, moderate, and severe, respectively.
Results: 84% patients in group A (betamethasone) showed >50% reduction in Scoring of Atopic Dermatitis
(SCORAD) whereas 94% patients in group B (NB-UVB) showed >50% reduction in SCORAD (p=0.554).
Recent research into the pathophysiology of atopic dermatitis
has yielded two new treatments--the first ones to receive US Food and Drug Administration (FDA) approval for management of this condition in more than a decade.
Canine atopic dermatitis
(CAD) is a common, recurring, inflammatory and pruritic allergic skin disease in dogs exhibiting characteristic clinical signs associated with IgE antibodies that is most commonly directed against environmental allergens (Halliwell, 2006).
Cordoro, MD, anyone who cares for patients with severe atopic dermatitis
understands the sense of misery that can ensue.